ATC Group: H02CA02 Osilodrostat

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of H02CA02 in the ATC hierarchy

Level Code Title
1 H Systemic hormonal preparations, excl. Sex hormones and insulins
2 H02 Corticosteroids for systemic use
3 H02C Antiadrenal preparations
4 H02CA Anticorticosteroids
5 H02CA02

Active ingredients in H02CA02

Active Ingredient

Osilodrostat is a cortisol synthesis inhibitor. It potently inhibits 11β-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. In Cushing’s disease, the fall in plasma cortisol concentration also stimulates ACTH secretion, via the feedback mechanism which accelerates steroid biosynthesis.

Related product monographs

Document Type Information Source  
 ISTURISA Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 ISTURISA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)

Medicines in this ATC group

United States (US)

Austria (AT)

Croatia (HR)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Poland (PL)

Romania (RO)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.